Kestra Advisory Services LLC Grows Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Kestra Advisory Services LLC boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 15.8% in the 1st quarter, Holdings Channel reports. The fund owned 221,492 shares of the biopharmaceutical company’s stock after purchasing an additional 30,297 shares during the period. Kestra Advisory Services LLC’s holdings in Bristol-Myers Squibb were worth $12,011,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Traynor Capital Management Inc. lifted its holdings in shares of Bristol-Myers Squibb by 2.8% during the 1st quarter. Traynor Capital Management Inc. now owns 7,672 shares of the biopharmaceutical company’s stock valued at $416,000 after acquiring an additional 207 shares in the last quarter. Fulton Breakefield Broenniman LLC lifted its holdings in shares of Bristol-Myers Squibb by 4.6% during the 4th quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 209 shares in the last quarter. Accurate Wealth Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 4.0% during the 1st quarter. Accurate Wealth Management LLC now owns 5,612 shares of the biopharmaceutical company’s stock valued at $304,000 after acquiring an additional 216 shares in the last quarter. Newbridge Financial Services Group Inc. lifted its holdings in shares of Bristol-Myers Squibb by 12.8% during the 1st quarter. Newbridge Financial Services Group Inc. now owns 1,910 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 216 shares in the last quarter. Finally, Bfsg LLC lifted its holdings in shares of Bristol-Myers Squibb by 24.4% during the 1st quarter. Bfsg LLC now owns 1,120 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 220 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Price Performance

BMY stock traded up $0.14 on Monday, hitting $50.59. 2,937,087 shares of the company’s stock traded hands, compared to its average volume of 15,828,417. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.41. The stock has a market cap of $102.55 billion, a price-to-earnings ratio of -16.27, a P/E/G ratio of 17.25 and a beta of 0.44. The stock has a fifty day moving average of $41.76 and a 200-day moving average of $46.76. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 11.52%. The business had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same period in the prior year, the business earned $1.75 earnings per share. The business’s quarterly revenue was up 8.7% on a year-over-year basis. On average, analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be given a $0.60 dividend. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 4.74%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BMY. Barclays lowered shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $41.00 price objective on the stock. in a report on Monday. BMO Capital Markets cut their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $55.79.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.